ZNTL Covered Call Strategy
ZNTL (Zentalis Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd.
ZNTL (Zentalis Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $303.6M, a beta of 2.00 versus the broader market, a 52-week range of 1.13-6.95, average daily share volume of 1.9M, a public-listing history dating back to 2020, approximately 166 full-time employees. These structural characteristics shape how ZNTL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.00 indicates ZNTL has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a covered call on ZNTL?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
Current ZNTL snapshot
As of May 15, 2026, spot at $4.04, ATM IV 161.00%, IV rank 40.03%, expected move 46.16%. The covered call on ZNTL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this covered call structure on ZNTL specifically: ZNTL IV at 161.00% is mid-range versus its 1-year history, so the credit collected on a ZNTL covered call sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 46.16% (roughly $1.86 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ZNTL expiries trade a higher absolute premium for lower per-day decay. Position sizing on ZNTL should anchor to the underlying notional of $4.04 per share and to the trader's directional view on ZNTL stock.
ZNTL covered call setup
The ZNTL covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ZNTL near $4.04, the first option leg uses a $4.24 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ZNTL chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ZNTL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $4.04 | long |
| Sell 1 | Call | $4.24 | N/A |
ZNTL covered call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
ZNTL covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on ZNTL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use covered call on ZNTL
Covered calls on ZNTL are an income strategy run on existing ZNTL stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
ZNTL thesis for this covered call
The market-implied 1-standard-deviation range for ZNTL extends from approximately $2.18 on the downside to $5.90 on the upside. A ZNTL covered call collects premium on an existing long ZNTL position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether ZNTL will breach that level within the expiration window. Current ZNTL IV rank near 40.03% is mid-range against its 1-year distribution, so the IV signal is neutral; the covered call thesis on ZNTL should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ZNTL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ZNTL-specific events.
ZNTL covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ZNTL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ZNTL alongside the broader basket even when ZNTL-specific fundamentals are unchanged. Short-premium structures like a covered call on ZNTL carry tail risk when realized volatility exceeds the implied move; review historical ZNTL earnings reactions and macro stress periods before sizing. Always rebuild the position from current ZNTL chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on ZNTL?
- A covered call on ZNTL is the covered call strategy applied to ZNTL (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With ZNTL stock trading near $4.04, the strikes shown on this page are snapped to the nearest listed ZNTL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ZNTL covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the ZNTL covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 161.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ZNTL covered call?
- The breakeven for the ZNTL covered call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ZNTL market-implied 1-standard-deviation expected move is approximately 46.16%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on ZNTL?
- Covered calls on ZNTL are an income strategy run on existing ZNTL stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current ZNTL implied volatility affect this covered call?
- ZNTL ATM IV is at 161.00% with IV rank near 40.03%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.